Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00010049 2018-06-27

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Phase 1/2 Completed

105 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Phase 2 Completed

91 enrolled 11 charts

GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00455559 2018-02-22

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Phase 2 Completed

40 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00324987 2017-09-14

S0502

Phase 3 Terminated

12 enrolled 13 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01172548 2017-05-31

INV555

Phase 2 Completed

132 enrolled

GastrointestinalSarcoma

Recurrence, Gastrointestinal Stromal Tumors

NCT01137916 2017-05-03

Study to Evaluate Imatinib in Desmoid Tumors

Phase 2 Completed

39 enrolled

Sarcoma

Desmoid Tumors

NCT00150072 2017-02-23

Efficacy and Safety of Imatinib in Chordoma

Phase 2 Completed

55 enrolled

Sarcoma

Chordoma

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Phase 2 Completed

38 enrolled

MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT00585221 2017-02-10

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Phase 2 Terminated

8 enrolled 4 charts

CNSGastrointestinalSarcoma

Brain Neoplasms, Gastrointestinal Stromal Tumors

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT01483014 2016-11-18

CONVERT

Phase 2 Completed

30 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00287846 2016-08-30

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Phase 1/2 Completed

40 enrolled

Sarcoma

Desmoid Tumors

NCT02576080 2015-10-15

GIGIST

Phase 3 Unknown

80 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Phase 1 Completed

37 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00293124 2015-08-13

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Phase 3 Completed

125 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02268435 2015-08-04

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

Phase 1 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Clinical Trials

PALANGI3

Imatinib TDM in GIST

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

ATEZOGIST

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

ImadGist

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Entacapone Combination With Imatinib for Treatment of GIST

Basket 1

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

GISTs

ALT GIST

SeliGIST

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

ZJGIST-01

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Radix

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

S0502

INV555

Study to Evaluate Imatinib in Desmoid Tumors

Efficacy and Safety of Imatinib in Chordoma

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

CONVERT

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

GIGIST

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors